600329 达仁堂
午间休市 08-26 11:29:37
资讯
新帖
简况
股市必读:达仁堂中报 - 第二季度单季净利润同比下降85.78%
证券之星 · 08-17
股市必读:达仁堂中报 - 第二季度单季净利润同比下降85.78%
达仁堂(600329)2026年中报简析:净利润同比下降66.55%
证券之星 · 08-16
达仁堂(600329)2026年中报简析:净利润同比下降66.55%
达仁堂(600329)6月30日股东户数5.93万户,较上期减少1.85%
证券之星 · 08-15
达仁堂(600329)6月30日股东户数5.93万户,较上期减少1.85%
达仁堂(600329)披露2026年半年度报告,8月14日股价下跌1.69%
证券之星 · 08-14
达仁堂(600329)披露2026年半年度报告,8月14日股价下跌1.69%
达仁堂最新公告:2026年半年度净利润6.45亿元同比下降66.55%
证券之星 · 08-14
达仁堂最新公告:2026年半年度净利润6.45亿元同比下降66.55%
股市必读:达仁堂新发布《达仁堂关于分公司获得药品注册证书的公告》
证券之星 · 08-10
股市必读:达仁堂新发布《达仁堂关于分公司获得药品注册证书的公告》
每周股票复盘:达仁堂(600329)获沙格列汀二甲双胍缓释片注册证
证券之星 · 08-09
每周股票复盘:达仁堂(600329)获沙格列汀二甲双胍缓释片注册证
达仁堂(600329)披露关于日常关联交易的公告,8月7日股价上涨0.84%
证券之星 · 08-07
达仁堂(600329)披露关于日常关联交易的公告,8月7日股价上涨0.84%
达仁堂拟与太平医药及津智医药签署年度分销协议
美股速递 · 08-07
达仁堂拟与太平医药及津智医药签署年度分销协议
达仁堂旗下新新制药厂获药品注册证书
美股速递 · 08-07
达仁堂旗下新新制药厂获药品注册证书
达仁堂:合作协议项下产品累计供应总额上限不超过1.13亿元
美股速递 · 08-07
达仁堂:合作协议项下产品累计供应总额上限不超过1.13亿元
达仁堂拟以关联交易方式涉足仓储物流合作
美股速递 · 08-07
达仁堂拟以关联交易方式涉足仓储物流合作
达仁堂(600329.SH):沙格列汀二甲双胍缓释片(Ⅰ)获药品注册证书
智通财经 · 08-06
达仁堂(600329.SH):沙格列汀二甲双胍缓释片(Ⅰ)获药品注册证书
股市必读:达仁堂新发布《达仁堂关于控股股东增持公司S股股份实施结果的公告》
证券之星 · 08-06
股市必读:达仁堂新发布《达仁堂关于控股股东增持公司S股股份实施结果的公告》
达仁堂(600329)披露控股股东增持公司S股股份实施结果公告,8月4日股价下跌0.11%
证券之星 · 08-04
达仁堂(600329)披露控股股东增持公司S股股份实施结果公告,8月4日股价下跌0.11%
股市必读:达仁堂新发布《达仁堂2026年第一次临时股东会决议公告》
证券之星 · 08-03
股市必读:达仁堂新发布《达仁堂2026年第一次临时股东会决议公告》
每周股票复盘:达仁堂(600329)召开临时股东会审议通过董事薪酬制度
证券之星 · 08-02
每周股票复盘:达仁堂(600329)召开临时股东会审议通过董事薪酬制度
达仁堂(600329)披露2026年第一次临时股东会决议公告,7月31日股价下跌0.03%
证券之星 · 07-31
达仁堂(600329)披露2026年第一次临时股东会决议公告,7月31日股价下跌0.03%
达仁堂(600329)披露召开2026年第一次临时股东会提示性公告,7月27日股价上涨1.01%
证券之星 · 07-27
达仁堂(600329)披露召开2026年第一次临时股东会提示性公告,7月27日股价上涨1.01%
每周股票复盘:达仁堂(600329)拟制定高管薪酬管理制度
证券之星 · 07-26
每周股票复盘:达仁堂(600329)拟制定高管薪酬管理制度
加载更多
公司概况
公司名称:
津药达仁堂集团股份有限公司
所属行业:
医药制造业
上市日期:
2001-06-06
主营业务:
津药达仁堂集团股份有限公司的主营业务是中药材、中成药、化学原料及制剂、营养保健品的研发制造及药品零售。公司的主要产品是速效救心丸、清咽滴丸、痹祺胶囊、通脉养心丸、牛黄清心丸、安宫牛黄丸、清肺消炎丸、清宫寿桃丸、胃肠安丸。集团创新建成“基于数智化‘中药全产业链溯源’质量管理模式”,凭借该质量管理模式,集团成功荣膺第六届天津质量奖正奖。
发行价格:
10.00
{"stockData":{"symbol":"600329","market":"SH","secType":"STK","nameCN":"达仁堂","latestPrice":36.54,"timestamp":1787714977000,"preClose":36.08,"halted":0,"volume":2178600,"delay":0,"changeRate":0.0127,"floatShares":567000000,"shares":770000000,"eps":1.1014,"marketStatus":"午间休市","change":0.46,"latestTime":"08-26 11:29:37","open":36.13,"high":36.94,"low":36.12,"amount":79902400,"amplitude":0.0227,"askPrice":36.55,"askSize":6,"bidPrice":36.54,"bidSize":76,"shortable":0,"etf":0,"ttmEps":1.1014,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787720400000},"marketStatusCode":3,"adr":0,"adjPreClose":36.08,"symbolType":"stock","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":39.69,"lowLimit":32.47,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":770094356,"isCdr":false,"pbRate":4.68,"roa":"--","peRate":33.175958,"roe":"9.06%","epsLYR":2.77,"committee":0.789744,"marketValue":28139000000,"turnoverRate":0.0038,"status":0,"floatMarketCap":20721000000},"requestUrl":"/m/hq/s/600329","defaultTab":"news","newsList":[{"id":"2660177059","title":"股市必读:达仁堂中报 - 第二季度单季净利润同比下降85.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660177059","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660177059?lang=zh_cn&edition=full","pubTime":"2026-08-17 00:59","pubTimestamp":1786899548,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,达仁堂报收于36.17元,下跌1.69%,换手率0.67%,成交量3.77万手,成交额1.37亿元。业绩披露要点:2026年中报归母净利润6.45亿元,同比下降66.55%;第二季度单季归母净利润2.21亿元,同比下降85.78%。第二季度单季度主营收入9.39亿元,同比下降21.4%;单季度归母净利润2.21亿元,同比下降85.78%;单季度扣非净利润2.21亿元,同比上升0.31%;负债率43.61%,毛利率76.02%,投资收益4927.2万元,财务费用93.19万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659179302","title":"达仁堂(600329)2026年中报简析:净利润同比下降66.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659179302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659179302?lang=zh_cn&edition=full","pubTime":"2026-08-16 06:01","pubTimestamp":1786831280,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期达仁堂发布2026年中报。根据财报显示,达仁堂净利润同比下降66.55%。截至本报告期末,公司营业总收入24.55亿元,同比下降7.39%,归母净利润6.45亿元,同比下降66.55%。按单季度数据看,第二季度营业总收入9.39亿元,同比下降21.4%,第二季度归母净利润2.21亿元,同比下降85.78%。本文数据来源于达仁堂2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600001204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659789121","title":"达仁堂(600329)6月30日股东户数5.93万户,较上期减少1.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659789121","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659789121?lang=zh_cn&edition=full","pubTime":"2026-08-15 17:02","pubTimestamp":1786784555,"startTime":"0","endTime":"0","summary":"证券之星消息,近日达仁堂披露,截至2026年6月30日公司股东户数为5.93万户,较3月31日减少1117.0户,减幅为1.85%。在中药行业个股中,达仁堂股东户数高于行业平均水平,截至6月30日,中药行业平均股东户数为5.38万户。从股价来看,2026年3月31日至2026年6月30日,达仁堂区间跌幅为9.0%,在此期间股东户数减少1117.0户,减幅为1.85%。根据统计,达仁堂2026年3月31日至2026年6月30日,主力资金净流出4.93亿元,游资资金净流入1568.57万元,散户资金净流入4.77亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081500012570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0060","BK0028","BK0239","BK0188","600329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659475611","title":"达仁堂(600329)披露2026年半年度报告,8月14日股价下跌1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659475611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659475611?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:11","pubTimestamp":1786716678,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,达仁堂报收于36.17元,较前一交易日下跌1.69%,最新总市值为278.54亿元。该股当日开盘36.7元,最高36.98元,最低36.06元,成交额达1.37亿元,换手率为0.67%。近日,津药达仁堂集团股份有限公司披露2026年半年度报告。公告显示,截至报告期末,公司总资产为10,533,346,049.72元,较上年度末减少9.89%;归属于上市公司股东的净资产为5,940,832,262.72元,较上年度末减少16.32%。经营活动产生的现金流量净额为832,090,265.76元,同比增加70.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400039843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600329","BK0164","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659433981","title":"达仁堂最新公告:2026年半年度净利润6.45亿元同比下降66.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659433981","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659433981?lang=zh_cn&edition=full","pubTime":"2026-08-14 18:30","pubTimestamp":1786703448,"startTime":"0","endTime":"0","summary":"达仁堂(600329.SH)公告称,公司发布2026年半年度报告,实现营业收入24.55亿元,同比下降7.39%;归属于上市公司股东的净利润6.45亿元,同比下降66.55%。注:公司Q2净利润2.21亿,Q1净利润4.24亿,据此计算,Q2净利润环比下降47%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400033047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658267007","title":"股市必读:达仁堂新发布《达仁堂关于分公司获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658267007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658267007?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:05","pubTimestamp":1786298713,"startTime":"0","endTime":"0","summary":"公司公告汇总达仁堂关于分公司获得药品注册证书的公告津药达仁堂集团股份有限公司新新制药厂近日收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)《药品注册证书》。达仁堂关于日常关联交易的公告津药达仁堂集团股份有限公司下属分公司拟与津药太平医药有限公司、天津中新医药有限公司签署《年度经销协议》,交易金额不超过11,300万元,协议有效期至2026年12月31日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0060","600329","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658467534","title":"每周股票复盘:达仁堂(600329)获沙格列汀二甲双胍缓释片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2658467534","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658467534?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:30","pubTimestamp":1786213829,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,达仁堂报收于37.18元,较上周的38.29元下跌2.9%。来自公司公告汇总:达仁堂新新制药厂获沙格列汀二甲双胍缓释片(Ⅰ)药品注册证书。交易信息汇总8月6日达仁堂发生一笔700.53万元的大宗交易。公司公告汇总达仁堂新新制药厂收到国家药监局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)《药品注册证书》,该药品为化学药品4类,适用于2型糖尿病成人患者,获批视同通过一致性评价,短期内对公司业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600329","BK0239","BK0188","BK0060","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644143","title":"达仁堂(600329)披露关于日常关联交易的公告,8月7日股价上涨0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644143?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:25","pubTimestamp":1786112751,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,达仁堂报收于37.18元,较前一交易日上涨0.84%,最新总市值为286.32亿元。近日,达仁堂发布《关于日常关联交易的公告》。交易构成关联交易,关联董事已回避表决,无需提交股东会审议。过去12个月内,公司与同一关联人累计发生关联交易金额4,349.43万元,占公司最近一期经审计归母净资产的0.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0188","600329","BK0028","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184711123","title":"达仁堂拟与太平医药及津智医药签署年度分销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1184711123","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184711123?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:48","pubTimestamp":1786106928,"startTime":"0","endTime":"0","summary":"达仁堂——这家老牌药企,正筹划一项重大布局。据透露,该公司提议与太平医药、津智医药达成一项年度分销协议。此举旨在深化渠道合作,进一步巩固其市场网络。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0060","BK0164","BK0239","600329","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119826429","title":"达仁堂旗下新新制药厂获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1119826429","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119826429?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:48","pubTimestamp":1786106907,"startTime":"0","endTime":"0","summary":"达仁堂(Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited)宣布,其下属的新新制药厂已正式收到药品注册证书。这一进展标志着该公司在药品研发与生产领域迈出了坚实一步,为后续产品上市铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","600329","BK0188","BK0164","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154018959","title":"达仁堂:合作协议项下产品累计供应总额上限不超过1.13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154018959","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154018959?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:47","pubTimestamp":1786106832,"startTime":"0","endTime":"0","summary":"达仁堂(Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited)近日披露,依据相关协议安排,其所供应产品的累计总价值上限被设定为人民币1.13亿元。这一数字,构成了合作框架下的关键约束条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","600329","BK0164","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142217559","title":"达仁堂拟以关联交易方式涉足仓储物流合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1142217559","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142217559?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:47","pubTimestamp":1786106829,"startTime":"0","endTime":"0","summary":"天津达仁堂集团——这家历史悠久的中药企业,正计划通过一项关联交易,正式切入仓储与物流的合作领域。此举,不仅标志着其业务版图的新拓展,更暗示着对供应链效率的深层考量。作为一项涉及利益相关方的交易,此次合作提案的提出,无疑将引发市场对于公司治理与战略布局的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","BK0239","600329","BK0164","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683526","title":"达仁堂(600329.SH):沙格列汀二甲双胍缓释片(Ⅰ)获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657683526?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:35","pubTimestamp":1786001738,"startTime":"0","endTime":"0","summary":"智通财经APP讯,达仁堂(600329.SH)发布公告,公司所属分公司津药达仁堂集团股份有限公司新新制药厂于近日收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(Ⅰ)《药品注册证书》。沙格列汀二甲双胍缓释片(Ⅰ),本品配合饮食和运动治疗,适合使用沙格列汀和二甲双胍治疗的2型糖尿病成人患者,以改善此类患者的血糖控制(详见说明书)。本品由百时美施贵宝与阿斯利康合作开发,在2型糖尿病长期血糖控制及糖尿病慢病管理领域具有广阔的市场应用前景。根据米内数据库显示,沙格列汀二甲双胍缓释片(Ⅰ)销量近年来始终保持显著增速,2025年国内总销售额约为4.8亿元,同比2024年增长约33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","BK0028","600329","BK0060","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529061","title":"股市必读:达仁堂新发布《达仁堂关于控股股东增持公司S股股份实施结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657529061?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:08","pubTimestamp":1785949694,"startTime":"0","endTime":"0","summary":"公司公告汇总:控股股东一致行动人完成S股增持,实际增持724,200股,增持金额约人民币1430.59万元,持股比例由42.997%升至43.091%。公司公告汇总达仁堂关于控股股东增持公司S股股份实施结果的公告津药达仁堂集团股份有限公司控股股东一致行动人津药国际有限公司于2026年2月6日披露拟在未来6个月内通过新加坡交易所增持公司S股股份,增持价格不高于4美元/股,增持金额为人民币1430万元至2859万元。本次增持未导致公司控股股东及实际控制人变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0188","BK0028","600329","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552925","title":"达仁堂(600329)披露控股股东增持公司S股股份实施结果公告,8月4日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552925","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552925?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:26","pubTimestamp":1785853580,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,达仁堂报收于37.81元,较前一交易日下跌0.11%,最新总市值为291.17亿元。近日,达仁堂发布《关于控股股东增持公司S股股份实施结果的公告》。公告显示,津药达仁堂集团股份有限公司于2026年2月6日披露控股股东一致行动人津药国际有限公司拟在未来6个月内通过新加坡交易所增持公司S股股份,增持价格不高于4美元/股,增持金额为人民币1,430万元至2,859万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600329","BK0060","BK0188","BK0239","BK0028","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343559","title":"股市必读:达仁堂新发布《达仁堂2026年第一次临时股东会决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343559?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:30","pubTimestamp":1785695433,"startTime":"0","endTime":"0","summary":"公司公告汇总:达仁堂于2026年7月31日召开2026年第一次临时股东会,审议通过《公司董事、高级管理人员薪酬管理制度》及《公司2026年度董事薪酬方案》两项议案。公司公告汇总达仁堂2026年第一次临时股东会决议公告津药达仁堂集团股份有限公司于2026年7月31日召开2026年第一次临时股东会,会议由董事长王磊主持,采用现场与网络投票结合方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0060","BK0239","BK0028","600329","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656731608","title":"每周股票复盘:达仁堂(600329)召开临时股东会审议通过董事薪酬制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2656731608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656731608?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:42","pubTimestamp":1785609732,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,达仁堂报收于38.29元,较上周的36.61元上涨4.59%。本周关注点公司公告汇总:达仁堂召开2026年第一次临时股东会,审议通过董事及高管薪酬管理制度与2026年度董事薪酬方案。达仁堂2026年第一次临时股东会决议公告津药达仁堂集团股份有限公司于2026年7月31日召开2026年第一次临时股东会,会议由董事长王磊主持,采用现场与网络投票结合方式召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600329","BK0164","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362449","title":"达仁堂(600329)披露2026年第一次临时股东会决议公告,7月31日股价下跌0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362449?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:23","pubTimestamp":1785507791,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,达仁堂报收于38.29元,较前一交易日下跌0.03%,最新总市值为294.87亿元。该股当日开盘37.9元,最高38.43元,最低37.86元,成交额达1.24亿元,换手率为0.58%。近日,达仁堂披露《2026年第一次临时股东会决议公告》。公告显示,津药达仁堂集团股份有限公司于2026年7月31日召开2026年第一次临时股东会,会议由董事长王磊主持,采用现场与网络投票结合方式召开。出席会议股东共824人,代表有表决权股份总数333,507,891股,占公司总股本的43.307%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100042049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0164","600329","BK0239","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395046","title":"达仁堂(600329)披露召开2026年第一次临时股东会提示性公告,7月27日股价上涨1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654395046?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:27","pubTimestamp":1785162434,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘,达仁堂报收于36.98元,较前一交易日上涨1.01%,最新总市值为284.78亿元。近日,达仁堂发布《关于召开2026年第一次临时股东会的提示性公告》。公告显示,津药达仁堂集团股份有限公司将于2026年7月31日召开2026年第一次临时股东会,会议采取现场投票与网络投票相结合方式,网络投票通过上海证券交易所系统进行。股东需于7月30日前完成参会登记,会议地点为天津市南开区白堤路17号达仁堂大厦会议室。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","600329","BK0239","BK0060","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654105733","title":"每周股票复盘:达仁堂(600329)拟制定高管薪酬管理制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2654105733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654105733?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:07","pubTimestamp":1785002830,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,达仁堂报收于36.61元,较上周的37.91元下跌3.43%。本周,达仁堂7月21日盘中最高价报39.39元。达仁堂当前最新总市值281.93亿元,在中药板块市值排名7/66,在两市A股市值排名663/5200。本周关注点公司公告汇总:达仁堂拟制定《公司董事、高级管理人员薪酬管理制度》,并提交2026年第一次临时股东会审议。薪酬与公司经营业绩和个人绩效挂钩,实施绩效薪酬追索与止付机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0188","BK0028","600329","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787715043504,"stockEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":-0.0145},{"period":"3month","weight":-0.0411},{"period":"6month","weight":-0.1132},{"period":"1year","weight":-0.1168},{"period":"ytd","weight":-0.1139}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"津药达仁堂集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2001-06-06","address":"天津市南开区白堤路17号","registeredCapital":"77009万元","survey":" 津药达仁堂集团股份有限公司的主营业务是中药材、中成药、化学原料及制剂、营养保健品的研发制造及药品零售。公司的主要产品是速效救心丸、清咽滴丸、痹祺胶囊、通脉养心丸、牛黄清心丸、安宫牛黄丸、清肺消炎丸、清宫寿桃丸、胃肠安丸。集团创新建成“基于数智化‘中药全产业链溯源’质量管理模式”,凭借该质量管理模式,集团成功荣膺第六届天津质量奖正奖。","listedPrice":10},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达仁堂(600329)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达仁堂(600329)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达仁堂,600329,达仁堂股票,达仁堂股票老虎,达仁堂股票老虎国际,达仁堂行情,达仁堂股票行情,达仁堂股价,达仁堂股市,达仁堂股票价格,达仁堂股票交易,达仁堂股票购买,达仁堂股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达仁堂(600329)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达仁堂(600329)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}